What SEC filings does Arbutus Biopharma Corporation submit to the SEC?

Arbutus Biopharma Corporation (ABUS) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about ABUS?

A Form 4 for ABUS discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Arbutus Biopharma Corporation?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for ABUS?

The 10-K is Arbutus Biopharma Corporation's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all ABUS SEC filings directly on EDGAR?

You can view all historical Arbutus Biopharma Corporation filings on the SEC EDGAR company page for ABUS. Each filing card on this page links directly to the original SEC document.

How often does Arbutus Biopharma Corporation file with the SEC?

Arbutus Biopharma Corporation files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling ABUS shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

ABUS SEC Filing News — Arbutus Biopharma Corporation

Latest SEC filings for Arbutus Biopharma Corporation (ABUS) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-07.

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reaw…

Sector: Healthcare Industry: Biotechnology Market Cap: $663.7M CIK: 1447028

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

What you're looking at: Each item below is parsed from an actual SEC filing submitted by Arbutus Biopharma Corporation. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.

ABUS Filing Activity Snapshot 2026-03-23 — 2026-10-07

Insider Transactions (Form 4)

0 buys vs 0 sells

Insider buying and selling activity is balanced in this period.

Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Arbutus Biopharma Corporation.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 5 disposition to issuer, 4 option exercise and 2 compensation award. None of the classified filings involved a discretionary open-market trade, so this period says nothing about what insiders think of the price.

What each transaction type means

Disposition to issuer ×5: Shares were surrendered to or repurchased by the issuer rather than sold to other investors.
Option exercise ×4: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Compensation award ×2: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Form 4 Disposition to issuer Tax / Compensation Filing 2026-10-07

ABUS insider Form 4 filed for equity award, exercise, or tax withholding

Beardsley Robert A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were surrendered to or repurchased by the issuer rather than sold to other investors.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer	17,948	$5.00	$89.7K

Filing: Form 4 (Insider Transaction) Insider: Beardsley Robert A (Director) Shares: 17,948

View on SEC EDGAR → Open Filing Document →

Form 4 Disposition to issuer Tax / Compensation Filing 2026-10-07

ABUS insider Form 4 filed for equity award, exercise, or tax withholding

Nguyen Tuan (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were surrendered to or repurchased by the issuer rather than sold to other investors.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer	48,081	$5.00	$240.4K

Filing: Form 4 (Insider Transaction) Insider: Nguyen Tuan (Chief Financial Officer) Shares: 48,081

View on SEC EDGAR → Open Filing Document →

Form 4 Disposition to issuer Tax / Compensation Filing 2026-10-07

ABUS insider Form 4 filed for equity award, exercise, or tax withholding

Sawhney Roger (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were surrendered to or repurchased by the issuer rather than sold to other investors.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer	17,142	$5.00	$85.7K

Filing: Form 4 (Insider Transaction) Insider: Sawhney Roger (Director) Shares: 17,142

View on SEC EDGAR → Open Filing Document →

Form 4 Disposition to issuer Tax / Compensation Filing 2026-10-07

ABUS insider Form 4 filed for equity award, exercise, or tax withholding

Androski Lindsay (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were surrendered to or repurchased by the issuer rather than sold to other investors.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer	24,655	$5.00	$123.3K

Filing: Form 4 (Insider Transaction) Insider: Androski Lindsay (Director, President and CEO) Shares: 24,655

View on SEC EDGAR → Open Filing Document →

Form 4 Disposition to issuer Tax / Compensation Filing 2026-10-05

ABUS insider Form 4 filed for equity award, exercise, or tax withholding

Roivant Sciences Ltd. (Director, 10% Owner) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were surrendered to or repurchased by the issuer rather than sold to other investors.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer	8,967,383	$5.00	$44.84M

Filing: Form 4 (Insider Transaction) Insider: Roivant Sciences Ltd. (Director, 10% Owner) Shares: 8,967,383

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-09-23

ABUS insider Form 4 filed for equity award, exercise, or tax withholding

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	116,408	$3.20	$372.5K
`M`	Option exercise	10,456	$4.39	$45.9K
`F`	Tax withholding on vested shares	82,527	$5.07	$418.4K
`M`	Option exercise derivative · Stock Option (Right to Buy)	116,408	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	10,456	—	—

Filing: Form 4 (Insider Transaction) Insider: Androski Lindsay (Director, President and CEO) Shares: 209,391

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-09-23

ABUS insider Form 4 filed for equity award, exercise, or tax withholding

Nguyen Tuan (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	265,625	$3.49	$927.0K
`M`	Option exercise	27,475	$4.39	$120.6K
`F`	Tax withholding on vested shares	206,637	$5.07	$1.05M
`M`	Option exercise derivative · Stock Option (Right to Buy)	265,625	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	27,475	—	—

Filing: Form 4 (Insider Transaction) Insider: Nguyen Tuan (Chief Financial Officer) Shares: 499,737

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-09-23

ABUS insider Form 4 filed for equity award, exercise, or tax withholding

Sawhney Roger (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	52,533	$3.34	$175.5K
`M`	Option exercise	78,800	$4.24	$334.1K
`F`	Tax withholding on vested shares	100,508	$5.07	$509.6K
`M`	Option exercise derivative · Stock Option (Right to Buy)	52,533	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	78,800	—	—

Filing: Form 4 (Insider Transaction) Insider: Sawhney Roger (Director) Shares: 231,841

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-09-23

ABUS insider Form 4 filed for equity award, exercise, or tax withholding

Beardsley Robert A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	52,533	$3.20	$168.1K
`M`	Option exercise	78,800	$4.24	$334.1K
`F`	Tax withholding on vested shares	99,057	$5.07	$502.2K
`M`	Option exercise derivative · Stock Option (Right to Buy)	52,533	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	78,800	—	—

Filing: Form 4 (Insider Transaction) Insider: Beardsley Robert A (Director) Shares: 230,390

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-10

ABUS insider Form 4 filed for equity award, exercise, or tax withholding

Sawhney Roger (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	78,800	—	—

Filing: Form 4 (Insider Transaction) Insider: Sawhney Roger (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-10

ABUS insider Form 4 filed for equity award, exercise, or tax withholding

Beardsley Robert A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	78,800	—	—

Filing: Form 4 (Insider Transaction) Insider: Beardsley Robert A (Director)

View on SEC EDGAR → Open Filing Document →

Material Events 7 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 7 in this period for Arbutus Biopharma Corporation. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-21